MedTrace Logo

Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects

NCT00981968 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2010-10-15

No results posted yet for this study

Summary

The purpose of this study is to investigate safety, tolerability and pharmacokinetics of sitaxentan following single and multiple oral administrations of sitaxentan sodium in Japanese healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

Sitaxentan sodium/Placebo

100 mg and 200 mg, tablet, single and multiple oral doses for 7 days

DRUG

Sitaxentan sodium/Placebo

100 mg and 200 mg, tablet, single oral dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00981968 on ClinicalTrials.gov